No Data
No Data
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients
Express News | 'DHl Supply Chain Expands Pharma Logistics Operations In France' - DHL Group
DHL Strikes Logistics Partnership With Sanofi
Deutsche Post (DHL.F), d/b/a DHL Group, said Monday it signed a long-term strategic partnership with Sanofi (SAN.PA) to help boost the French drugmaker's logistics network. Under the deal, the German
The judge ruled that the Zantac cancer lawsuit will continue to be heard. GlaxoSmithKline (GSK.US) plunged 10% in pre-market trading.
According to Zhītōng Cáijīng APP, a judge in Delaware has made an important ruling, approving the continuation of more than 70,000 lawsuits against GlaxoSmithKline (GSK.US) and its production of Zantac, a medication used for the treatment of heartburn, which is alleged to have caused cancer. This decision has dealt a significant blow to GlaxoSmithKline, with its stock price plummeting by as much as 10% before the opening bell on Monday, the largest drop since mid-2022. It is understood that Zantac (generic name Ranitidine) is commonly used to treat and prevent heartburn as well as excess stomach acid.
GSK Plunges as Drugmaker Must Face Zantac Cases in Delaware
Market Chatter: Sanofi Enlists Banks for EUR20 Billion Consumer Health Spinoff, IPO
Sanofi (SAN.PA) enlisted bankers as it moves forward with plans for a consumer health spin-off valued at 20 billion euros, London's Financial Times reported Sunday, citing people familiar with the mat
No Data